Patient description: A 42-year-old healthy woman came to the clinic to have her flu shot in early October. She works in a rehab center and has no underlying disease. It's her first time getting the vaccine this year. She is married for 5 years and uses barrier methods of contraception. Her menstrual cycle is irregular. She does not smoke. She is not on any medications. She exercises regularly for 30 minutes a day at least 5 days a week. She has no history of allergies to any food or drugs. Her past surgical history is significant for tonsillectomy and she is otherwise healthy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cervical Cancer criteria. 1. Patients who give their written consent to participate in the study. 2. Women, 18-70 years of age, considering the following • In women of childbearing age: i. Negative serum pregnancy test at baseline (14 days prior to the start of QT-RT). ii. The patient must accept the use of any contraceptive method approved by the attending physician during the study and 12 weeks after the end of treatment. • Postmenopausal women must meet at least one of the following parameters for i. Prior bilateral oophorectomy ii. Age ≥ 60 years iii. Age < 60 years, with amenorrhea for at least 12 months and levels of follicle stimulating hormone and estradiol within postmenopausal parameters. 3. Diagnosed with CC IB2-IVA, with or without retroperitoneal lymph nodes (para-aortic), smaller than 2 cm. 4. With histologic confirmation of squamous carcinoma, adenosquamous carcinoma, adenocarcinoma or glassy cells carcinoma. 5. Without previous treatment and medically able to receive gemcitabine. 6. Disease measurable by CT and/or MRI according to (v1.1) criteria. 7. Functional status of 0-3 according to WHO criteria. 8. Renal dysfunction defined by glomerular filtration (GF) <60 ml/min/1.73m2 calculated by the CKD-EPI formula. 9. Normal hematologic and liver function, as defined by the following parameters Hemoglobin > 10g/L. (Transfusion prior to the treatment is allowed to reach this level of hemoglobin) Leucocytes > 4000/mm3 Platelets > 100,000/mm3 Total Bilirubin ≤1.5 times the upper normal limit (UNL) Transaminases < 1.5 times the UNL. 10. Normal PA chest radiograph   1. Patients with prior or concomitant malignancy, except non-melanoma skin carcinoma. 2. Patients with diabetes and/or hypertension with retinopathy or albuminuria >300. 3. Patients with evidence of active TB infection. 4. Patients infected with Human Immunodeficiency Virus (HIV). 5. Patients with a history of Systemic Lupus Erythematosus and other rheumatologic diseases that cause kidney damage. 6. Patients with vesicovaginal or vesicorectal fistula at the time of diagnosis. 7. Patients with uncontrolled intercurrent diseases including active infections that contraindicate QT, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, decompensated diabetes, difficult control hypertension and psychiatric illness. 8. Concomitant treatment with other experimental drugs. 9. Social, family or geographical conditions that suggest a poor adherence to the study. Study discontinuation criteria. 1. Evidence of disease progression, if the researcher considers that the patient would benefit more with other therapy. 2. At the request of the patient. 3. By unacceptable toxicity. 4. Pregnancy. Violation of starting criteria. must be followed punctually. If a patient were inappropriately included, she must be discontinued from the study